Anteris Technologies Global Corp. (“ATGC”) announced today that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for the proposed initial public offering (IPO) of its common stock in the U.S. (the “Offering”). All shares of common stock in the Offering will be sold by ATGC.
The specific amount of common stock to be offered and the price range have yet to be determined. The Offering is subject to market conditions, and there are no guarantees regarding the timing, size, price, or other terms of the Offering.
ATGC plans to list its common stock on the Nasdaq Global Select Market under the symbol “AVR.” Additionally, after the IPO, ATGC intends to list its CHESS Depositary Interests (CDIs)—which represent underlying shares of common stock on a 1:1 basis—on the Australian Securities Exchange under the same symbol, “AVR.”
TD Cowen, Barclays, and Cantor are acting as joint book-running managers for the proposed Offering, with Lake Street Capital Markets serving as lead manager.
The Offering will be made only through a prospectus. Once available, a preliminary prospectus for the Offering can be obtained from TD Securities (USA) LLC, Barclays, or Cantor, as listed in the full announcement.
A registration statement for the common stock has been filed with the SEC but has not yet become effective. No shares can be sold, nor can offers be accepted, until the registration statement is effective.
About ATGC: ATGC was incorporated on January 29, 2024, to reorganize the operations of Anteris Technologies Ltd (Anteris), an Australian public company, into a Delaware-based parent company.
About Anteris Technologies Ltd (ASX: AVR): Anteris Technologies Ltd (ASX: AVR) is a leading structural heart company focused on developing innovative medical devices. Headquartered in Australia, with a significant presence in Minneapolis, USA, Anteris specializes in solutions for structural heart disease.
Anteris’ flagship product, DurAVR®, is a transcatheter heart valve (THV) for treating aortic stenosis. This is the first TAVR device to use a single piece of bioengineered tissue, mimicking the natural human aortic valve’s shape and function. DurAVR® is made with ADAPT® tissue, a patented anti-calcification technology used in over 55,000 patients worldwide.
The ComASUR® Delivery System allows precise deployment and placement of the DurAVR® valve, designed for optimal alignment with the heart’s native commissures.
